At the 2026 ASCO Annual Meeting, a phase 3 trial led by Prof. Caicun Zhou from Shanghai East Hospital was orally presented on May 29, 2026. OptiTROP-Lung05 is the first phase 3 trial evaluating a TROP2 ADC (sacituzumab trimetocan, sac-TMT) plus immunotherapy in first-line PD-L1-positive advanced NSCLC.

Study Design: Rigorous randomization,comprehensive stratified assessment
413 patients with previously untreated, EGFR/ALK-negative, PD-L1-positive (TPS≥1%) locally advanced or metastatic NSCLC were randomized 1:1 to sac-TMT (4mg/kg Q2W) + pembrolizumab (400mg Q6W) (n=208) vs pembrolizumab alone (400mg Q6W) (n=205). Stratification by PD-L1 expression (TPS 1-49% vs ≥50%), histology (squamous vs non-squamous), and ECOG score. Primary endpoint: PFS by BICR per RECIST 1.1.

Significant PFS benefit with broad advantages across multiple subgroups
As of Sept 29, 2025, median follow-up 10.5 months. Median PFS (BICR): not reached vs 5.7 months; HR=0.35 (95% CI 0.26-0.47); p<0.0001. OS HR=0.55 (95% CI 0.36-0.85). ORR: 70.2% vs 42.0%.

In PD-L1 TPS 1-49% subgroup, PFS HR=0.28; in TPS≥50%, HR=0.47. In non-squamous, HR=0.28; in squamous, HR=0.44.


Overall manageable safety profile with no new safety signals
Grade ≥3 TEAEs: 55.3% in combination arm vs 31.4% in monotherapy arm. Most common grade ≥3 TEAEs with sac-TMT: neutrophil count decreased (17.3%), anemia (9.1%), stomatitis (5.3%). Discontinuation due to TEAEs: sac-TMT 3.8%, pembrolizumab 5.3% (combination) vs pembrolizumab 4.9% (monotherapy).
Chinese-originated ADC ushers in a new era of first-line lung cancer therapy
Conclusion: This first phase 3 trial demonstrates that a Chinese-originated ADC plus pembrolizumab provides significant PFS benefit over pembrolizumab alone in first-line PD-L1-positive advanced NSCLC, with manageable safety. The combination has potential to become a new standard of care.